Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%

Alector, Inc.

2025-Q3 EPS reported -$1.05 revenue$14,808,000

Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.
Cash $291.1M, with $20M ATM proceeds Sep-Oct 2025; runway through 2027.
Lead candidates selected: AL137 (ABC anti-amyloid beta, IND 2026) and AL050 (ABC GCase, IND 2027).
Latozinemab Phase 3 INFRONT-3 failed; open-label extension discontinued.
Implemented ~47% workforce reduction in Oct 2025 to focus on priority programs.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.